NASDAQ:QURE - Uniqure Stock Price, Price Target & More

$29.80 +1.02 (+3.54 %)
(As of 04/25/2018 04:00 PM ET)
Previous Close$28.78
Today's Range$28.60 - $30.79
52-Week Range$4.72 - $32.71
Volume222,763 shs
Average Volume373,431 shs
Market Capitalization$987.15 million
P/E Ratio-10.14
Dividend YieldN/A
Beta0.18

About Uniqure (NASDAQ:QURE)

Uniqure logouniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics, and Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Receive QURE News and Ratings via Email

Sign-up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:QURE
CUSIPN/A
Phone31-20-566-7394

Debt

Debt-to-Equity Ratio0.22%
Current Ratio8.46%
Quick Ratio8.46%

Price-To-Earnings

Trailing P/E Ratio-10.14
Forward P/E Ratio-9.28
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.11 million
Price / Sales72.22
Cash FlowN/A
Price / CashN/A
Book Value$2.90 per share
Price / Book10.28

Profitability

EPS (Most Recent Fiscal Year)($2.94)
Net Income$-79,260,000.00
Net Margins-604.72%
Return on Equity-174.25%
Return on Assets-46.88%

Miscellaneous

Employees202
Outstanding Shares31,770,000

How to Become a New Pot Stock Millionaire

Uniqure (NASDAQ:QURE) Frequently Asked Questions

What is Uniqure's stock symbol?

Uniqure trades on the NASDAQ under the ticker symbol "QURE."

How were Uniqure's earnings last quarter?

Uniqure NV (NASDAQ:QURE) posted its quarterly earnings data on Wednesday, March, 14th. The biotechnology company reported ($0.91) EPS for the quarter, missing the Zacks' consensus estimate of ($0.68) by $0.23. The biotechnology company had revenue of $2.58 million for the quarter, compared to the consensus estimate of $2.83 million. Uniqure had a negative net margin of 604.72% and a negative return on equity of 174.25%. View Uniqure's Earnings History.

When is Uniqure's next earnings date?

Uniqure is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Uniqure.

What price target have analysts set for QURE?

7 brokerages have issued twelve-month price objectives for Uniqure's shares. Their forecasts range from $13.00 to $35.00. On average, they anticipate Uniqure's share price to reach $23.8333 in the next twelve months. View Analyst Ratings for Uniqure.

Are investors shorting Uniqure?

Uniqure saw a drop in short interest in April. As of April 13th, there was short interest totalling 751,751 shares, a drop of 29.8% from the March 30th total of 1,070,529 shares. Based on an average trading volume of 322,800 shares, the days-to-cover ratio is currently 2.3 days. Currently, 3.9% of the company's shares are short sold.

Who are some of Uniqure's key competitors?

Who are Uniqure's key executives?

Uniqure's management team includes the folowing people:
  • Mr. Matthew Craig Kapusta, CEO, Interim CFO & Exec. Director (Age 46)
  • Dr. Sander Van Deventer, Co-Founder, Chief Scientific Officer, Director, Advisor & GM of Amsterdam (Age 64)
  • Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
  • Dr. Scott T. McMillan Ph.D., Chief Operating Officer (Age 59)
  • Mr. Christian Klemt, Chief Accounting Officer (Age 45)

Has Uniqure been receiving favorable news coverage?

Press coverage about QURE stock has been trending somewhat positive recently, according to Accern. Accern scores the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Uniqure earned a media sentiment score of 0.18 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 46.03 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Uniqure?

Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Uniqure's stock price today?

One share of QURE stock can currently be purchased for approximately $29.80.

How big of a company is Uniqure?

Uniqure has a market capitalization of $987.15 million and generates $13.11 million in revenue each year. The biotechnology company earns $-79,260,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis. Uniqure employs 202 workers across the globe.

How can I contact Uniqure?

Uniqure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-566-7394 or via email at [email protected]


MarketBeat Community Rating for Uniqure (QURE)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  386 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  572
MarketBeat's community ratings are surveys of what our community members think about Uniqure and other stocks. Vote "Outperform" if you believe QURE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QURE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Uniqure (NASDAQ:QURE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Uniqure in the last 12 months. Their average twelve-month price target is $23.8333, suggesting that the stock has a possible downside of 20.02%. The high price target for QURE is $35.00 and the low price target for QURE is $13.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.752.752.71
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.8333$21.5714$19.8571$14.40
Price Target Upside: 20.02% downside2.38% upside0.19% upside5.01% downside

Uniqure (NASDAQ:QURE) Consensus Price Target History

Price Target History for Uniqure (NASDAQ:QURE)

Uniqure (NASDAQ:QURE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/23/2018HC WainwrightSet Price TargetBuy$35.00HighView Rating Details
3/20/2018Janney Montgomery ScottReiterated RatingBuy$30.00HighView Rating Details
11/24/2017OppenheimerReiterated RatingHoldLowView Rating Details
11/7/2017Leerink SwannBoost Price Target$19.00 -> $26.00N/AView Rating Details
11/7/2017Evercore ISIInitiated CoverageOutperform -> Outperform$22.00N/AView Rating Details
7/23/2017Chardan CapitalSet Price TargetBuy$13.00HighView Rating Details
5/24/2017CowenReiterated RatingBuyMediumView Rating Details
4/12/2017Jefferies GroupReiterated RatingHold$8.00LowView Rating Details
12/6/2016WallachBeth CapitalLower Price TargetBuy$27.00 -> $15.00N/AView Rating Details
11/15/2016Piper JaffrayDowngradeOverweight -> NeutralN/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Uniqure (NASDAQ:QURE) Earnings History and Estimates Chart

Earnings by Quarter for Uniqure (NASDAQ:QURE)

Uniqure (NASDAQ:QURE) Earnings Estimates

2018 EPS Consensus Estimate: ($2.90)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.81)($0.81)($0.81)
Q2 20181($0.80)($0.80)($0.80)
Q3 20181($0.81)($0.81)($0.81)
Q4 20181($0.48)($0.48)($0.48)

Uniqure (NASDAQ QURE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018        
3/14/2018Q4 2017($0.68)($0.91)$2.83 million$2.58 millionViewN/AView Earnings Details
11/1/2017Q3 2017($0.65)($0.40)$7.60 million$2.26 millionViewN/AView Earnings Details
8/8/20176/30/2017($0.78)($0.83)$2.92 million$4.94 millionViewN/AView Earnings Details
5/9/20173/31/2017($0.64)($0.80)$4.20 million$3.32 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.52)($0.58)$6.60 million$9.13 millionViewN/AView Earnings Details
11/22/2016Q3 2016($0.86)($0.60)$4.10 million$7.21 millionViewN/AView Earnings Details
8/25/2016Q2 2016($0.87)($0.98)$4.08 million$1.82 millionViewN/AView Earnings Details
5/31/2016Q1($0.8220)($0.9250)$2.94 million$4.30 millionViewN/AView Earnings Details
4/4/2016Q415($0.60)($0.58)$2.78 million$6.78 millionViewN/AView Earnings Details
11/30/2015Q315($0.64)($1.1410)$7.76 million$3.50 millionViewListenView Earnings Details
8/27/2015Q215($0.56)($0.9820)$31.18 million$1.79 millionViewN/AView Earnings Details
6/11/2015Q1($0.8160)($0.69)$9.50 million$1.17 millionViewN/AView Earnings Details
4/6/2015($0.62)($0.77)$1.38 million$1.61 millionViewN/AView Earnings Details
12/1/2014($0.53)($0.61)$2.00 million$1.30 millionViewN/AView Earnings Details
9/2/2014Q214($0.55)($1.35)$1.40 million$1.37 millionViewN/AView Earnings Details
6/6/2014($0.45)($0.52)$0.84 million$1.59 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Uniqure (NASDAQ:QURE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Uniqure (NASDAQ QURE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.73%
Institutional Ownership Percentage: 42.77%
Insider Trading History for Uniqure (NASDAQ:QURE)
Insider Trading History for Uniqure (NASDAQ:QURE)

Uniqure (NASDAQ QURE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2018Matthew C KapustaCEOSell39,169$21.72$850,750.68439,764View SEC Filing  
1/29/2018David SchafferDirectorSell2,878$18.53$53,329.3415,314View SEC Filing  
1/29/2018Deventer Sander VanInsiderSell5,985$18.53$110,902.05View SEC Filing  
1/4/2018Matthew C. KapustaCEOSell21,690$19.87$430,980.30View SEC Filing  
1/3/2018Christian KlemtInsiderSell5,093$20.13$102,522.09View SEC Filing  
1/3/2018Maria E. CantorSVPSell5,864$20.13$118,042.32View SEC Filing  
6/29/2017Harald PetryInsiderSell49,300$6.02$296,786.0027,753View SEC Filing  
6/27/2017Harald PetryInsiderSell65,930$6.01$396,239.30155View SEC Filing  
6/26/2017Harald PetryInsiderSell58,075$6.01$349,030.75155View SEC Filing  
6/22/2017Harald PetryInsiderSell155$6.00$930.00155View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Uniqure (NASDAQ QURE) News Headlines

Source:
DateHeadline
uniQure Delivers Oral Presentation on Broad Set of PreclinicuniQure Delivers Oral Presentation on Broad Set of Preclinic
www.lse.co.uk - April 25 at 5:09 PM
uniQure Delivers Oral Presentation on Broad Set of Preclinical Data on AMT-130 in Huntingtons Disease at the 2018 ...uniQure Delivers Oral Presentation on Broad Set of Preclinical Data on AMT-130 in Huntington's Disease at the 2018 ...
globenewswire.com - April 25 at 5:09 PM
uniQure Delivers Oral Presentation on Broad Set of Preclinical Data on AMT-130 in Huntington’s Disease at the 2018 American Academy of Neurology Annual MeetinguniQure Delivers Oral Presentation on Broad Set of Preclinical Data on AMT-130 in Huntington’s Disease at the 2018 American Academy of Neurology Annual Meeting
finance.yahoo.com - April 25 at 5:09 PM
Uniqure (QURE) Given a $35.00 Price Target at HC WainwrightUniqure (QURE) Given a $35.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 23 at 9:48 AM
Opinion: Harry Boxers biotech-stock breakouts to watchOpinion: Harry Boxer's biotech-stock breakouts to watch
www.marketwatch.com - April 20 at 8:55 AM
Uniqure (QURE) Rating Increased to Hold at ValuEngineUniqure (QURE) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - April 16 at 7:35 PM
Analyst Ratings for UniQure and Its Peers in April 2018Analyst Ratings for UniQure and Its Peers in April 2018
finance.yahoo.com - April 13 at 5:06 PM
An In-Depth Look at UniQure’s Cash Flows and ValuationAn In-Depth Look at UniQure’s Cash Flows and Valuation
finance.yahoo.com - April 13 at 5:06 PM
Insights into UniQure’s Financial PerformanceInsights into UniQure’s Financial Performance
finance.yahoo.com - April 13 at 5:06 PM
UniQure’s Promising Research PipelineUniQure’s Promising Research Pipeline
finance.yahoo.com - April 13 at 5:06 PM
Uniqure (QURE) Lifted to Buy at BidaskClubUniqure (QURE) Lifted to Buy at BidaskClub
www.americanbankingnews.com - April 13 at 10:45 AM
How Do Analysts See uniQure NV. (NASDAQ:QURE) Performing In The Next Couple Of Years?How Do Analysts See uniQure NV. (NASDAQ:QURE) Performing In The Next Couple Of Years?
finance.yahoo.com - April 13 at 9:00 AM
Zacks: Brokerages Expect Uniqure NV (QURE) Will Announce Quarterly Sales of $3.08 MillionZacks: Brokerages Expect Uniqure NV (QURE) Will Announce Quarterly Sales of $3.08 Million
www.americanbankingnews.com - April 13 at 2:35 AM
Zacks Investment Research Upgrades Uniqure (QURE) to HoldZacks Investment Research Upgrades Uniqure (QURE) to Hold
www.americanbankingnews.com - April 12 at 12:33 PM
Opinion: Harry Boxers five biotech stocks to watchOpinion: Harry Boxer's five biotech stocks to watch
www.marketwatch.com - April 11 at 5:03 PM
Zacks: Analysts Expect Uniqure NV (QURE) to Announce -$0.74 Earnings Per ShareZacks: Analysts Expect Uniqure NV (QURE) to Announce -$0.74 Earnings Per Share
www.americanbankingnews.com - April 11 at 3:10 PM
Uniqure Sees Unusually High Options Volume (QURE)Uniqure Sees Unusually High Options Volume (QURE)
www.americanbankingnews.com - April 10 at 8:03 AM
Novartis Wager on AveXis Shows Rare Diseases Command Mega PricesNovartis Wager on AveXis Shows Rare Diseases Command Mega Prices
www.bloomberg.com - April 9 at 4:57 PM
Novartis CEO Spurs Rare-Disease Shift With $8.7 Billion DealNovartis CEO Spurs Rare-Disease Shift With $8.7 Billion Deal
www.bloomberg.com - April 9 at 8:59 AM
Zacks Investment Research Upgrades Uniqure (QURE) to "Hold"Zacks Investment Research Upgrades Uniqure (QURE) to "Hold"
www.americanbankingnews.com - April 7 at 7:02 AM
After $1 Million Drug Flop, UniQure Seeks Gene-Therapy RevivalAfter $1 Million Drug Flop, UniQure Seeks Gene-Therapy Revival
www.bloomberg.com - April 6 at 9:00 AM
Uniqure (QURE) Stock Rating Upgraded by Zacks Investment ResearchUniqure (QURE) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 5 at 11:19 PM
Uniqure (QURE) Stock Rating Lowered by BidaskClubUniqure (QURE) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 4 at 9:30 AM
ValuEngine Upgrades Uniqure (QURE) to BuyValuEngine Upgrades Uniqure (QURE) to Buy
www.americanbankingnews.com - April 3 at 10:07 AM
Uniqure NV (QURE) Given Consensus Recommendation of "Buy" by AnalystsUniqure NV (QURE) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 1 at 3:30 PM
Evercore ISI Begins Coverage on Uniqure (QURE)Evercore ISI Begins Coverage on Uniqure (QURE)
www.americanbankingnews.com - April 1 at 3:10 PM
Uniqure (QURE) Downgraded to "Sell" at Zacks Investment ResearchUniqure (QURE) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 5:16 PM
Uniqure (QURE) Downgraded to "Hold" at BidaskClubUniqure (QURE) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - March 28 at 12:00 AM
$3.08 Million in Sales Expected for Uniqure NV (QURE) This Quarter$3.08 Million in Sales Expected for Uniqure NV (QURE) This Quarter
www.americanbankingnews.com - March 27 at 3:58 AM
Uniqure (QURE) Upgraded to "Buy" at BidaskClubUniqure (QURE) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - March 24 at 6:46 PM
Janney: Buy The Dip In Uniqure - BenzingaJanney: Buy The Dip In Uniqure - Benzinga
www.benzinga.com - March 21 at 9:41 AM
Janney: Buy The Dip In UniqureJanney: Buy The Dip In Uniqure
finance.yahoo.com - March 20 at 4:52 PM
Uniqure (QURE) Given Buy Rating at Janney Montgomery ScottUniqure (QURE) Given Buy Rating at Janney Montgomery Scott
www.americanbankingnews.com - March 20 at 12:35 PM
Insider Selling: Uniqure NV (QURE) CEO Sells 39,169 Shares of StockInsider Selling: Uniqure NV (QURE) CEO Sells 39,169 Shares of Stock
www.americanbankingnews.com - March 19 at 4:14 PM
Report: Developing Opportunities within Itau Unibanco Banco Holding SA, NantHealth, Southern First Bancshares, uniQure N.V., Ascendis Pharma A/S, and National General — Future Expectations, Projections Moving into 2018Report: Developing Opportunities within Itau Unibanco Banco Holding SA, NantHealth, Southern First Bancshares, uniQure N.V., Ascendis Pharma A/S, and National General — Future Expectations, Projections Moving into 2018
finance.yahoo.com - March 16 at 8:55 AM
Uniqure (QURE) Stock Rating Reaffirmed by HC WainwrightUniqure (QURE) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - March 15 at 2:11 PM
BRIEF-UniQure ‍on Track To Begin Pivotal Study Of AMT-061 In Hemophilia B In Q3BRIEF-UniQure ‍on Track To Begin Pivotal Study Of AMT-061 In Hemophilia B In Q3
www.reuters.com - March 14 at 6:30 PM
uniQure Announces 2017 Financial Results and Recent Company Progress - NasdaquniQure Announces 2017 Financial Results and Recent Company Progress - Nasdaq
www.nasdaq.com - March 14 at 9:23 AM
Form 8-K uniQure NV For: Mar 14 - StreetInsider.comForm 8-K uniQure NV For: Mar 14 - StreetInsider.com
www.streetinsider.com - March 14 at 9:23 AM
uniQure reports FY results - Seeking AlphauniQure reports FY results - Seeking Alpha
seekingalpha.com - March 14 at 9:23 AM
uniQure Announces 2017 Financial Results and Recent Company ProgressuniQure Announces 2017 Financial Results and Recent Company Progress
finance.yahoo.com - March 14 at 9:23 AM
Uniqure NV (QURE) Expected to Announce Quarterly Sales of $2.83 MillionUniqure NV (QURE) Expected to Announce Quarterly Sales of $2.83 Million
www.americanbankingnews.com - March 10 at 8:40 AM
Uniqure NV (QURE) Given Consensus Rating of "Buy" by AnalystsUniqure NV (QURE) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 7 at 3:45 PM
Royce & Associates LP Takes Position in Uniqure NV (QURE)Royce & Associates LP Takes Position in Uniqure NV (QURE)
www.americanbankingnews.com - March 6 at 10:53 AM
Prosight Management LP Purchases New Position in Uniqure NV (QURE)Prosight Management LP Purchases New Position in Uniqure NV (QURE)
www.americanbankingnews.com - March 5 at 4:38 PM
181,378 Shares in Uniqure NV (QURE) Purchased by Bogle Investment Management L P DE181,378 Shares in Uniqure NV (QURE) Purchased by Bogle Investment Management L P DE
www.americanbankingnews.com - March 4 at 4:54 AM
Uniqure NV (QURE) Short Interest UpdateUniqure NV (QURE) Short Interest Update
www.americanbankingnews.com - March 3 at 1:54 AM
uniQure to Participate in Multiple Conferences in March - GlobeNewswire (press release)uniQure to Participate in Multiple Conferences in March - GlobeNewswire (press release)
globenewswire.com - February 27 at 8:50 AM
uniQure to Participate in Multiple Conferences in MarchuniQure to Participate in Multiple Conferences in March
finance.yahoo.com - February 27 at 8:50 AM
66,270 Shares in Uniqure NV (QURE) Purchased by Victory Capital Management Inc.66,270 Shares in Uniqure NV (QURE) Purchased by Victory Capital Management Inc.
www.americanbankingnews.com - February 25 at 5:52 AM

SEC Filings

Uniqure (NASDAQ:QURE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Uniqure (NASDAQ:QURE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Uniqure (NASDAQ QURE) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.